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ABSTRACT
The therapeutic potential of RNA interference (RNAi) has been limited by 
inefficient delivery of short interfering RNA (siRNA). Tumor-specific recognition can 
be effectively achieved by antibodies directed against highly expressed cancer cell 
surface receptors. We investigated the utility of linking an internalizing streptavidin-
conjugated HER2 antibody to an endosome-disruptive biotinylated polymeric 
nanocarrier to improve the functional cytoplasmic delivery of siRNA in breast and 
ovarian cancer cells in vitro and in an intraperitoneal ovarian cancer xenograft model 
in vivo, yielding an 80% reduction of target mRNA and protein levels with sustained 
repression for at least 96 hours. RNAi-mediated site specific cleavage of target mRNA 
was demonstrated using the 5’ RLM-RACE (RNA ligase mediated-rapid amplification 
of cDNA ends) assay. Mice bearing intraperitoneal human ovarian tumor xenografts 
demonstrated increased tumor accumulation of Cy5.5 fluorescently labeled siRNA 
and 70% target gene suppression after treatment with HER2 antibody-directed siRNA 
nanocarriers. Detection of the expected mRNA cleavage product by 5’ RLM-RACE assay 
confirmed that suppression occurs via the expected RNAi pathway. Delivery of siRNA 
via antibody-directed endosomolytic nanoparticles may be a promising strategy for 
cancer therapy.
INTRODUCTION
The discovery of the RNA interference (RNAi) 
mechanism over a decade ago by Andrew Fire and 
Craig Mello stimulated intense interest in the potential 
application of short interfering RNA (siRNA), not only 
as a useful tool for the mechanistic study of cellular 
pathways but more significantly as a novel disease 
therapeutic. The ensuing years have resulted in a flurry 
of preclinical investigations and early phase clinical trials 
designed to test the utility of siRNA for the treatment of 
a variety of human diseases. [1, 2] In particular, siRNA 
for suppression of genes critical for tumor growth 
or resistance to chemotherapy may improve clinical 
outcomes and patient survival. The demonstration of the 
RNAi-mediated mechanism of target mRNA cleavage in 
human tumors from patients treated in Phase I clinical 
trials provides hope for clinical use of siRNA, however, 
the major obstacle of cell specific delivery remains to be 
overcome. [3, 4]
The selective recognition of tumors by antibodies 
has been harnessed to directly elicit apoptosis, stimulate 
the immune-mediated clearance of cancer cells, or 
target cytotoxic agents to cancer cells. HER2 (also 
known as ERBB2 or NEU) is an internalizing cell 
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surface receptor overexpressed or mutated in a variety 
of solid tumors including breast, gastric, lung and 
ovarian cancers. [5–9] Treatment with trastuzumab, a 
humanized mouse antibody directed against HER2, has 
become the standard of care for HER2-overexpressing 
breast cancer [6] and HER2-overexpressing metastatic 
gastric cancer. [10] HER2 has additionally been 
investigated as a portal through which receptor targeted 
antibodies or aptamers can deliver peptides, [11–13] 
siRNA [14, 15] or small molecule drugs [16] into cells. 
Recently, a drug conjugated form of trastuzumab (ado-
trastuzumab emtansine) that facilitates the intracellular 
delivery of the cytotoxic microtubule inhibiting agent 
mertansine was approved for the treatment of metastatic 
breast cancer. [17] Trastuzumab in combination with 
chemotherapy improved outcomes in gastric cancer 
patients, but single agent trastuzumab in ovarian cancer 
patients did not extend survival, although patients were 
selected for the clinical trial using relatively insensitive 
immunohistochemical assays without any confirmation 
of HER2 gene amplification status. [10, 18]
We previously developed a modular siRNA delivery 
system using a biotinylated endosome disrupting polymer 
that permits facile testing of combinations of antibody and 
siRNA and can be potentially tailored to various tumor 
types. [19] We hypothesized that a trastuzumab-directed 
siRNA nanoparticle could be used to enhance target gene 
suppression in HER2-overexpressing ovarian cancer 
cells. Ovarian cancer remains the most deadly cancer in 
women primarily due to its advanced state at diagnosis 
and rapid development of drug resistance. Little progress 
has been made over the past 20 years in improving the 
overall survival of patients, approximately 40% at 5 years, 
underscoring the need for novel therapeutic agents. [20]
Our group previously demonstrated the effectiveness 
of siRNA delivery to cells in vitro via a pH-sensitive 
endosomolytic diblock co-polymer carrier bearing an 
internalizing antibody directed against the CD22 receptor 
expressed on lymphoma cells. [19] The linear carrier 
consists of: 1) a pH-responsive ampholyte block of 
poly(DMAEMA) (dimethylaminoethyl methacrylate), 
BMA (butylmethacrylate), and PAA (propylacrylic acid) 
groups; 2) a cationic poly(DMAEMA) block for binding 
siRNA; and 3) a terminal biotin to enable linkage to a 
streptavidin-conjugated monoclonal antibody (mAb-
SA). Electrostatic interactions promote complexation of 
siRNA to the polymeric micelles (Figure 1a). Targeted 
nanoparticles are formed by subsequent addition of mAb-
SA which attach to exposed surface biotin on micelles. 
Binding of antibody to cognate antigen stimulates 
receptor-mediated endocytosis and uptake into the 
tumor cell (Figure 1b). Subsequent protonation of PAA 
in the acidic environment of late endosomes induces a 
conformational change to predominantly hydrophobic 
unimers, disrupting the endosomal membrane and 
releasing siRNA into the cytoplasm. The modularity of 
this system permits testing of combinations of antibodies 
and siRNA customized to different tumor types. We sought 
to demonstrate the versatility and effectiveness of our 
polymer carrier system both in vitro and in vivo using the 
HER2 antibody, trastuzumab, in a solid tumor xenograft 
model of ovarian cancer.
RESULTS
Intracellular uptake of nanoparticles by HER2-
overexpressing cancer cells
Binding and internalization of the trastuzumab-
polymer siRNA nanoparticle was confirmed by flow 
cytometry in both HER2-overexpressing SKOV3 ovarian 
cancer and SKBR3 breast cancer cells using fluorescent 
AlexaFluor 647 labelled siRNA (Figure 2). Fluorescence 
intensity after 1 hour of incubation was markedly higher 
in cells exposed to nanoparticles targeted with streptavidin-
conjugated trastuzumab (Trast-SA) compared to non-
targeted bovine herpes virus-1 antibody conjugate (BHV1-
SA) or naked nanoparticles. Confocal microscopy of 
SKOV3 cells 24 hours after treatment with AlexaFluor 647 
labeled siRNA showed a punctate pattern of fluorescence 
consistent with endocytic uptake (Figure 2). Enhanced 
uptake was similarly observed in SKOV3 cells using a 
different HER2 antibody 10H8 which recognizes a separate 
epitope on the HER2 receptor (Supplementary Figure S1a).
RNAi-mediated suppression via HER2 antibody-
linked siRNA carrier
Functional delivery was assessed in both HER2-
overexpressing ovarian and breast cancer cells using siRNA 
directed against the ubiquitously expressed glyceraldehyde-
3-phosphate dehydrogenase (GAPD) enzyme gene. Two 
hour pulse treatment of SKOV3 ovarian cancer cells with 
Trast-SA targeted nanoparticles containing GAPD siRNA 
resulted in greater reduction of GAPD expression at 48 hours 
compared to BHV1-SA as assessed by quantitative RT-PCR 
(Figure 3a) and GAPD enzyme activity (Supplementary 
Figure S1b). Verification of the RNAi mechanism of gene 
suppression was accomplished by the detection of the 
predicted 281 base pair fragment of GAPD mRNA using 
the 5’ RLM-RACE assay (RNA ligase-mediated rapid 
amplification of cDNA ends) (Figure 3b). Sequencing of 
the isolated fragment verified that cleavage occurred at the 
expected site in the GAPD mRNA. Robust suppression 
of the GAPD gene was demonstrated for at least 96 hours 
after 2 hour pulse treatment of luciferase-expressing 
SKOV3 EA8 cells (Figure 3c). GAPD gene suppression 
was similarly demonstrated in the HER2-overexpressing 
breast cancer cell lines SKBR3 and BT-474 (Supplementary 
Figure S2). Treatment of cells with nanoparticles did not 
elicit cytotoxicity nor induce TLR-3 (toll-like receptor 3) 
activated immune response genes STAT1 (signal transducer 
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and activator of transcription-1) or OAS1 (2’-5’ oligoadenylate 
synthetase-1) genes (Supplementary Figure S3).
In order to demonstrate that suppression could 
be achieved using different clinically relevant siRNA 
sequences, we tested the functional delivery of siRNA 
designed against genes associated with chemotherapy 
resistance. High levels of BCL-XL (B-cell lymphoma-extra 
large, also known as BCL2L1 or BCL2-like-1) are found 
in platinum resistant ovarian cancer cells and inhibition 
of BCL-XL confers sensitivity to chemotherapeutic 
agents. [21, 22] STAT3 (signal transducer and activator 
of transcription-3) has been shown to upregulate BCL-XL 
in solid tumors. [23] Significant suppression of BCL-XL 
was demonstrated in SKOV3 EA8 cells pulse treated for 
Figure 1: Antibody-targeted nanoparticle formation and intracellular siRNA delivery. a. The biotinylated diblock copolymer 
carrier consists of two modules: (1) a biotinylated cationic block comprised of poly(DMAEMA) and (2) an amphiphilic block consisting of 
DMAEMA, BMA and PPA groups. The linear polymer chains spontaneously form polymeric micelles with biotin exposed on the surface 
of the micelles. Polyplexes are formed by adding siRNA which associate with micelles via electrostatic interactions. Antibody-streptavidin 
conjugates (mAb-SA) are added and attach to available biotin moieties on the polymeric micelle surface resulting in antibody-targeted 
nanoparticles. b. Intracellular delivery is initiated by the recognition and binding of the antibody targeted nanoparticle to the cognate 
internalizing cell surface antigen on the surface of the tumor cell. Receptor-mediated endocytosis is triggered and the nanoparticle is 
internalized into the cell. As endosomal maturation occurs, the pH in the endosomal compartment drops and carboxyl groups in the amphilic 
block are protonated causing a conformational change of the polymer. This exposes the hydrophobic BMA side groups and disrupts the 
endosomal membrane leading to release of siRNA. siRNA is incorporated into the cytoplasmic RISC complex leading to catalytic cleavage 
of target mRNA and reduction of gene expression.
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Figure 2: HER2 antibody conjugate Trast-SA enhances the uptake of siRNA-containing nanoparticles into HER2-
overexpressing SKOV3 ovarian and SKBR3 breast cancer cells. a. SKOV3 and b. SKBR3 cells were treated continuously for 1 
hour with Trast-SA or BHV1-SA bearing nanoparticles or naked nanoparticles containing AlexaFluor 647 (AF647) labeled siRNA, trypsinized, 
then analyzed by flow cytometry for median relative fluorescence intensity (RFI). Representative results of 2 separate experiments are shown. 
c-e. SKOV3 cells grown on chambered glass slides were treated for 2 hours with (c) fluorescent AF647 labeled siRNA alone or contained within 
(d) BHV1-SA or (e) Trast-SA bearing nanoparticles prior to being rinsed and incubated with medium without nanoparticles. After 24 hours, cells 
were fixed, counterstained with mounting medium containing DAPI DNA stain, then visualized by fluorescence microscopy. Images were taken 
with a DeltaVision Elite wide deconvolution microscope at the original magnification of 80X. For each panel (c-e), both the fluorescence image 
(right) and fluorescence image merged with its respective differential interference contrast image (left) are shown. Scale bar equals 20 microns.
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Figure 3: Suppression of GAPD gene expression by Trast-SA polymer mediated siRNA delivery in SKOV3 ovarian 
cancer cells. a. SKOV3 cells were incubated for 2 hours in triplicate wells with GAPD or negative control siRNA contained in nanoparticles 
bearing Trast-SA or BHV1-SA conjugates or the respective antibody conjugates alone. Medium containing nanoparticles was then replaced 
with fresh medium alone and cells subsequently harvested 48 hours after the initial treatment and RNA extracted for qRT-PCR. Results 
are representative of three separate experiments. b. Verification of mRNA suppression via an RNAi mechanism was performed on SKOV3 
cells that were pulse treated for 2 hours with Trast-SA bearing nanoparticles containing either GAPD or negative control siRNA and RNA 
extracted 48 hours later for qRT-PCR and 5’RLM-RACE analysis. The bar graph demonstrates reduction of target GAPD mRNA levels as 
measured by qRT-PCR in cells treated with GAPD but not control siRNA. Below the graph, gel electrophoresis of 5’ RLM-RACE assay 
products from the respective treatments showed the predicted 281 base pair GAPD mRNA cleavage product only in the Trast-SA GAPD 
siRNA treated but not control siRNA or untreated cells supporting an RNAi mechanism for reduced GAPD expression. c. Sustained 
suppression of GAPD expression was observed in SKOV3 EA8 luciferase expressing cells treated for 2 hours with Trast-SA containing 
GAPD siRNA then analyzed for GAPD mRNA level via qRT-PCR at various timepoints after treatment.
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2 hours with Trast-SA targeted nanoparticles containing 
BCL-XL siRNA (Figure 4a) and showed an expected 
dose response with increasing siRNA concentrations 
(Figure 4b). The predicted 309 base pair mRNA cleavage 
product was demonstrated by the 5’RLM-RACE assay 
in cells treated with BCL-XL siRNA but not negative 
control siRNA (Figure 4c). The mRNA cleavage product 
identity was verified by sequencing the cDNA band 
purified from the gel. Reduction of BCL-XL protein in 
cells was demonstrated by Western blot analysis (Figure 
4d). Similar results were shown using a second BCL-XL 
siRNA sequence (data not shown). Reduction of STAT3 
mRNA was shown with qRT-PCR. Pretreatment with 
Trast-SA conjugate blocked HER2-mediated uptake of 
Trast-SA bearing nanoparticles containing STAT3 siRNA 
as demonstrated by reduction of STAT3 gene suppression 
to a level comparable to that achieved with non-targeting 
BHV1-SA conjugate (Figure 4e).
Localization of siRNA to intraperitoneal ovarian 
tumor with HER2 antibody
Ovarian cancer spreads locally within the abdominal 
cavity leading to tumor studding of peritoneal surfaces, 
blockage of lymphatic drainage and development of 
ascites. We used an intraperitoneal xenograft mouse 
model to recapitulate the typical clinical presentation in 
patients. Since assessment of intraperitoneal tumor burden 
by palpation is unreliable, we utilized the luciferase-
expressing SKOV3 clone EA8 to permit visualization 
of tumors in vivo with bioluminescence imaging. Mice 
bearing SKOV3 EA8 intraperitoneal ovarian tumors were 
imaged after luciferin injection by the IVIS Xenogen 
imaging system and separated into treatment groups 
with similar tumor burden as measured by average 
bioluminescence intensity. Mice were then injected with 
siRNA labeled with the near-infrared dye Cy5.5. Mice 
were sacrificed and organs were removed and imaged 
in an ex vivo fashion. We observed enhanced in vivo 
localization of siRNA delivered by trastuzumab-directed 
polymer to intraperitoneal ovarian tumors. Combined 
bioluminescence and fluorescence imaging after 24 hours 
revealed the accumulation of Cy5.5 siRNA in the kidneys 
whereas Cy5.5 siRNA administered within trastuzumab-
targeted nanoparticles was still present in tumors at this 
timepoint (Figure 5a, 5b). Quantification of Cy5.5 was 
accomplished by homogenizing tissue and measuring the 
amount of Cy5.5 fluorescence relative to a standard curve 
generated by a known quantity of Cy5.5 labeled siRNA. 
This revealed a marked accumulation of Cy5.5 in tumors 
removed from mice treated with Trast-SA bearing siRNA 
nanoparticles compared to free siRNA. Tumors from mice 
treated with Trast-SA targeted nanoparticles contained an 
average of 228 picomoles of Cy5.5 per gram of tumor 
tissue compared to 11 picomoles in tumors from mice 
treated with non-targeted siRNA, p=0.005 (Figure 5c). 
Comparison of the amount of Cy5.5 in tumor and kidney 
showed an average tumor to kidney ratio of 0.6 versus 
50 (p=0.04) in mice treated with non-targeted siRNA or 
Trast-SA targeted siRNA respectively (data not shown). 
The average tumor to liver ratio of Cy5.5 was 1.8 versus 
39 (p=0.002) in mice treated with non-targeted siRNA or 
Trast-SA targeted siRNA, respectively (data not shown).
Effective suppression of target genes in 
intraperitoneal ovarian tumors
Functional delivery of GAPD siRNA to tumors 
in vivo was investigated. Mice bearing intraperitoneal 
SKOV3 EA8 tumors were divided into groups with a 
similar average tumor bioluminescence and treated with 
the following: PBS, Trast-SA alone, BHV1-SA targeted 
nanoparticles containing GAPD siRNA or Trast-SA 
targeted nanoparticles containing either control or GAPD 
siRNA. Mice were treated daily for two consecutive 
days at a dose of 4 mg/kg siRNA, then sacrificed 72 
hours after the last dose. Intraperitoneal tumors were 
excised and RNA extracted. Reduction of GAPD gene 
expression by 70% with Trast-SA targeted nanoparticles 
containing GAPD siRNA was demonstrated via qRT-PCR 
compared to a 25% reduction with BHV1-SA non-targeted 
nanoparticles (Figure 6a). Additional mice were treated 
on the same schedule but at a dose of 2 mg/kg siRNA 
(Figures 6b, 6c). The 281 base pair predicted GAPD 
mRNA cleavage product was detected using the 5’RLM-
RACE assay in ovarian tumor tissue derived from mice 
treated with Trast-SA bearing nanoparticles containing 
GAPD siRNA but not in mice treated with Trast-SA 
nanoparticles containing negative control siRNA or Trast-
SA alone thus verifying RNAi-mediated GAPD gene 
suppression (Figure 6c). No induction of TLR3-activated 
immune response genes (OAS1 and STAT1) was detected 
(Supplementary Figure S4a, 4b). A minor three-fold 
increase in expression of mouse Ifit1 (interferon-induced 
protein with tetratricopeptide repeats-1), another marker 
of immune response, was detected in the spleens of mice 
treated with siRNA containing nanoparticles bearing either 
Trast-SA or BHV1-SA (Supplementary Figure S4). No 
marked changes in pancreatic, hepatic, or renal function, 
nor elevation in creatinine kinase or glucose were detected 
between treatment groups (data not shown).
DISCUSSION
Effective intracellular delivery to target cells in vivo 
is undoubtedly the most difficult hurdle to overcome in 
the development of oligonucleotide therapeutics. Early 
phase clinical trials testing therapeutic siRNA in humans 
have shown favorable results, but it is still uncertain which 
delivery vehicle will ultimately prove to be the most 
effective for clinical application. We present encouraging 
preclinical data testing a modular antibody-directed 
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Figure 4: Effective suppression of oncogenes Bcl-xL and STAT3 in cancer cells. SKOV3 EA8 cells were treated for 2 hours 
with nanoparticles bearing Trast-SA or BHV1-SA conjugates and containing 25 nM siRNA directed against BCL-XL or a scrambled negative 
control bearing no homology to any known gene sequence. Cells were rinsed to remove medium containing nanoparticles and fresh medium 
introduced. After 48 hours, cells were harvested and RNA collected for a. qRT-PCR analysis and c. detection of the expected 309 base pair 
BCL-XLmRNA fragment (red arrow) by the 5’RLM-RACE assay. SKOV3 EA8 cells were similarly treated for 2 hours with Trast-SA targeted 
nanoparticles at a dose range (15 to 50 nM) of BCL-XL siRNA or negative control siRNA at 25 or 50 nM. RNA or protein was collected at 
48 hours for b. qRT-PCR analysis and d. Western blot respectively. Results from cells treated with 25 nM or 50 nM negative control siRNA 
are shown since BCL-XL expression levels did not vary by negative control siRNA dose. HER2 receptors on SKOV3 EA8 cells were blocked 
by incubation with 37.5 nM of Trast-SA alone for 30 minutes prior to 2 hour incubation with Trast-SA targeted polyplexes containing 25 nM 
siRNA directed against STAT3. Other cells were treated with nanoparticles containing negative control or STAT3 siRNA bearing the indicated 
antibody conjugate targeting without preincubation. RNA was harvested 48 hours later and STAT3 levels assessed by qRT-PCR e. All qRT-
PCR analyses were performed for triplicate samples with standard deviation shown. Similar results were observed in duplicate experiments.
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Figure 5: Intraperitoneal ovarian tumor localization of Cy5.5 fluorescently labeled siRNA after administration 
of HER2 targeted carrier. Athymic mice were injected intraperitoneally with SKOV3 EA8 luciferase expressing cells and tumor 
establishment verified by bioluminescence imaging using the Xenogen IVIS system. Two weeks after tumor cell injection, 4 mice per 
treatment group were injected with phosphate buffered saline (PBS), 2 mg/kg Cy 5.5 labelled siRNA alone or contained within Trast-
SA targeted nanoparticles. Twenty-four hours later, mice were injected with luciferin, euthanized, and organs (heart, lungs, liver, spleen, 
kidneys, tumor) removed. Tissues were imaged ex vivo for both a. bioluminescence to identify luciferase expressing tumor cells and b. 
fluorescence to visualize siRNA biodistribution. c. Tumor tissue was weighed, homogenized in PBS and pelleted. Cy5.5 fluorescence 
intensity in the supernatant was measured at 675 nm excitation and 694 nm emission wavelength. The picomolar amount of Cy5.5 per gram 
in each tissue was determined by relating the measured fluorescence to a standard curve generated by known quantities of Cy5.5 siRNA.
Oncotarget9569www.impactjournals.com/oncotarget
Figure 6: RNAi mediated target gene silencing within intraperitoneal ovarian cancer tumors after HER2 antibody 
directed siRNA delivery. Athymic mice bearing intraperitoneal SKOV3 EA8 tumors verified by bioluminescence imaging were treated 
with Trast-SA or BHV1-SA conjugate bearing nanocarriers containing negative control or GAPD siRNA, Trast-SA alone or PBS at doses 
of a. 4 mg/kg (n=5 mice per group) or b, c. 2 mg/kg siRNA (n=3 mice per group) for two doses administered 24 hours apart. Mice were 
sacrificed 72 hours after the second dose and tumors collected for (a,b) qRT-PCR analysis and (c) detection of the 281 base pair GAPD 
mRNA cleavage product by 5’RLM-RACE assay. Error bars represent the standard deviation for qRT-PCR analyses. Asterisk indicates a 
significant difference (p<0.01) using the Student t-Test with one-tailed distribution between Trast-SA GAPD and BHV1-SA GAPD.
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biotinylated polymer carrier that can be easily adapted 
to different tumor types by varying the combination of 
antibody conjugate and target siRNA sequence.
We have demonstrated that this antibody-
directed carrier can deliver functionally active siRNA 
to both ovarian and breast cancer cells overexpressing 
HER2. Two internalizing HER2 antibody conjugates 
(trastuzumab and 10H8) that recognize separate epitopes 
effectively facilitated intracellular delivery of siRNA. 
Non-specific limited uptake of particles bearing non-
targeting BHV1-SA was observed and may be largely 
due to macropinocytosis which can be upregulated in 
cancer cells. [24] Blocking HER2 receptors with free 
Trast-SA conjugate prior to treatment with trastuzumab-
bearing nanoparticles reduced the level of suppression to 
that seen with non-targeting BHV1-SA, supporting the 
presence of an alternate pathway of uptake independent 
of HER2 receptor binding. The residual cationic charge 
on nanoparticles can promote non-specific association 
with negatively charged components on the cell 
surface membrane. Charge neutral carriers may reduce 
spontaneous non-targeted cellular uptake and our group 
is exploring alternative non-cationic carrier chemistries 
that utilize direct covalent disulfide linkage of siRNA to 
polymer rather than electrostatic interaction. [25] These 
neutral carriers are effective in vitro but require a higher 
siRNA concentration and longer continuous incubation 
time to achieve a level of gene suppression comparable 
to the antibody-targeted cationic diblock polymer used 
in the studies described in this report. Incorporation of 
an internalizing antibody or ligand moiety to the neutral 
siRNA carrier may counteract any loss of cellular uptake 
due to diminished charge interaction and improve the 
specificity of delivery and reduce the in vivo toxicity that 
can be observed with cationic carriers. Efforts to test this 
hypothesis are ongoing.
Verification of the intended mechanism of action 
is important in evaluating the efficacy of a therapeutic 
carrier. Detection of the predicted target mRNA cleavage 
product by 5’RLM-RACE is the gold standard for 
confirmation of RNAi-mediated gene suppression. [26] 
We showed that the predicted mRNA cleavage products 
were detectable both by size on agarose gel electrophoresis 
and by sequencing of the PCR product using two different 
siRNAs designed against either GAPD or BCL-XL genes 
in cultured ovarian cancer cells. Furthermore, site specific 
cleavage of target mRNA was detected in mouse xenograft 
ovarian tumor tissue (Figure 6c) supporting the functional 
in vivo activity of siRNA delivered by HER2-targeted 
polymer carrier. Because activation of TLR3 by polymer-
mediated siRNA delivery can lead to unintended effects 
from activation of the innate immune response, induction 
of OAS1 and STAT1 genes was assessed in tumors and 
found not to be upregulated in vivo. However, mouse 
Ifit1 gene expression was increased approximately 3 
to 4-fold in mouse spleen after treatment with Trast-SA 
or BHV1-SA targeted nanoparticles suggesting modest 
immune response activation. The significance of this low 
level of Ifit1upregulation is uncertain. Notably, siRNA 
treated mice exhibited no difference in behavior or 
appearance than mice receiving PBS alone. In comparison, 
a lipid-based carrier has been shown to induce a 247-
fold increase of Ifit1 mRNA expression and detectable 
serum interferon alpha levels in mice treated with 2 mg/
kg unmodified siRNA compared to PBS treatment. [27] 
Mitigation of the immune response may be achieved by 
use of 2’O-methyl modification of siRNA sequences [27] 
or pretreatment with dexamethasone. [28]
In conclusion, we have demonstrated the successful 
in vitro and in vivo antibody-targeted functional delivery 
of siRNA to HER2-overexpressing cancer cells. RNAi-
mediated cleavage of target mRNA was verified as the 
mechanism of gene suppression. Antibody-targeted 
nanoparticle delivery of siRNA incorporating endosomolytic 
polymer carriers may be a useful strategy for cancer therapy. 
Similar targeted carriers to deliver small molecule drugs or 
peptides may also be promising. Future directions include 
testing therapeutic siRNA sequences both as monotherapy 
and in combination with chemotherapy with in vivo cancer 
models. Evaluation of other internalizing receptors expressed 
on a higher proportion of ovarian tumors than HER2 such as 
mesothelin is also of interest. [29]
MATERIALS AND METHODS
Cell lines and media
The SKOV3, SKBR3 and BT-474 cell lines were 
obtained from the American Type Culture Collection 
(ATCC; Manassas, VA). Authentication of the cell line was 
assured by the provider. All three of these cell lines have 
HER2 gene amplification and overexpression. Multiple 
aliquots were frozen from cells continuously passaged 
no longer than 3 months after initial receipt. Cells for 
experiments were passaged continuously for no longer 
than 3 months before being discarded and fresh aliquots 
resuscitated. The SKOV3 luciferase-expressing clone EA8 
was generated by retroviral transduction of SKOV3 cells 
with a retrovirus encoding the firefly luciferase-Thy1.1-
Neo construct [30] followed by flow cytometric sorting 
for Thy1.1 expression and selection of Thy1.1 expressing 
cells with G418. SKOV3 EA8 was subsequently cloned by 
limiting dilution. All cell culture reagents were obtained 
from Invitrogen (Carlsbad, CA) except for fetal bovine 
serum (FBS) obtained from Thermo Scientific Hyclone 
(Logan, UT). SKOV3, SKOV3 EA8 and SKBR3 cells 
were grown in RPMI containing 10% fetal bovine serum, 
100 IU/ml penicillin, 100 mcg/ml streptomycin, and 2 
mM L-glutamine with the addition of 800 mcg/ml G418 
for the SKOV3 EA8 cells. BT-474 cell lines were grown 
in Hybri-Care Medium (ATCC) with 10% FBS. All cells 
were maintained at 37°C in 95% air/5% CO2 incubator.
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Polymer and antibody streptavidin conjugates
Polymer was synthesized as previously described.
[19] BHV1 (IgG1 anti-bovine herpes virus-1 antibody) 
was produced from a hybridoma obtained from ATCC and 
purified from ascites fluid over a HiTrap Protein G HP column 
(GE Healthcare; Piscataway, NJ). Trastuzumab used for 
experiments was clinical grade (Genentech; San Francisco, 
CA). 10H8 (an internalizing antibody to HER2) was produced 
in the laboratory of Michael F. Press (University of Southern 
California) as published. [31] Streptavidin conjugations to 
trastuzumab, BHV1 and 10H8 antibodies were performed 
by Donald K. Hamlin (University of Washington) using 
previously published techniques. [32, 33]
Polymeric micelle formation and transfection
Polymeric micelles were reconstituted from 
lyophilized polymer to a concentration of 1 mg/ml or 10 
mg/ml in sterile PBS for in vitro or in vivo experiments 
respectively as previously described. [19] Polymer was 
added to siRNA at a polymer:siRNA molar ratio of 3:1 
and incubated for 30 minutes at room temperature. The 
mAb-SA conjugates were added to polyplexes at 1:1 
conjugate to available biotin molar ratios. Dynamic 
light scattering measurements of the polymeric micelles 
and siRNA complexes (N/P ratio = 3) in 150 mM PBS 
at pH 7.4 yielded hydrodynamic diameters of 34 nm and 
37 nm respectively. The surface charge of the siRNA-
polymer complexes (N/P ratio = 3), based on ζ-potential 
measurements was found to be 4 mV, which suggests that 
particles are slightly positive under these conditions.
Cells were plated at a cell density of 50,000/
well in triplicate on the day prior to treatment. Cells 
were treated with polyplexes for 2 hours in medium 
containing 5% FBS followed by a medium change to 
10% FBS. Cells were harvested at 48 or 72 hours post-
treatment for RNA and protein extraction respectively. 
The siRNA sequences were as follows: glyceraldehyde-3-
phosphate dehydrogenase (GAPD) (sense strand 5’-GGU 
CGGAGUCAACGGAUUUTT-3’; Integrated DNA 
Technol ogies; Coralville, IA); STAT3 (sense strand 
5’-GCCUCUCUG CAGAAUUCAATT-3’, Integrated 
DNA Technologies); BCL-XL (sense strand 5’-GCUGGA 
GUCAGUUUAGAUGATT-3’; siRNA ID# s1921; sense 
strand 5’-GGAACUCUAUGGGAACAAUTT-3’; siRNA 
ID# s1922, Ambion); Ambion In Vivo GAPDH siRNA 
Cat#4457291; Ambion In Vivo Bcl2L1 Cat#4457308; 
Silencer Negative Control #1 siRNA (Catalog AM4611; 
Ambion).
Flow cytometry
Cells were plated at 200,000/well in 12-well 
plates the day prior to treatment. Polyplexes were 
formed as above using AlexaFluor 647-labeled AllStars 
Negative Control siRNA (#1027287; Invitrogen) and 
added to cells in media containing 5% FBS at a final 
concentration of 20 nM of siRNA. After incubation at 
37°C to allow internalization, cells were trypsinized 
and acid washed to remove residual surface bound 
nanoparticles and intracellular fluorescence measured 
on a BD FACS Canto flow cytometer with untreated 
cells set as a background reference as previously 
described. [19]
Fluorescence microscopy
SKOV3 EA8 cells were plated at 50,000/well in 
2-well chamber slides and allowed to adhere overnight. 
Polyplexes were formed as above using AlexaFluor 
647-labeled AllStars Negative Control siRNA 
(#1027287; Invitrogen) and added to cells in media 
containing 5% FBS at a final concentration of 25 nM 
of siRNA. After incubation at 37 °C for 2 hours, cells 
were rinsed to remove unbound nanoparticles and fresh 
medium added. After 24 hours, cells were rinsed three 
times in PBS, fixed with 10% neutral buffered formalin 
for 15 minutes, and rinsed again in PBS prior to being 
coverslipped with Prolong Gold antifade reagent with 
DAPI (Invitrogen). Random fields were imaged at 60x 
(oil) with a DeltaVision Elite wide-field deconvolution 
microscope (Applied Precision, Issaquah, WA) fitted 
with a Photometrics HQ scientific grade cooled CCD 
camera and an Olympus 60×/1.42 Plan Apochromatic 
objective. Acquisition settings were constant for the 
AlexaFluor 647 signal. Three-dimensional data sets 
consisting of optical sections at 0.2 micron spacing were 
collected with the manufacturer's SoftWoRx software, 
and deconvolved using a constrained iterative algorithm. 
Data sets were processed to normalize intensities to 
the same scale using SoftWoRx software. Merging the 
data sets with their respective differential interference 
contrast (DIC) images was done with public domain 
software ImageJ.
Quantitative RT-PCR
RNA was isolated using the RNeasy mini kit 
(Qiagen; Valencia, CA) and reverse transcribed using 
TaqMan Reverse Transcription reagents (Applied 
Biosystems; Carlsbad, CA). PCR reactions were run 
in duplicate using an ABI Prism 7900HT real-time 
PCR instrument. Primers with FAM and VIC-labeled 
compatible probes for multiplex PCR were obtained 
from Applied Biosystems: GAPD (Catalog#4352934E), 
peptidylprolyl isomerase A (PPIA) (Catalog#4326316E), 
BCL-XL (Hs00236329_m1), STAT3 (Hs00374280_m1), 
STAT1 (Hs01013996_m1), OAS1 (Hs00973637_m1), 
mouse Ifit1(Mm00515153_m1). Relative quantification 
of gene expression was based on the reference value from 
the untreated control. [34]
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5’-RLM-RACE and sequencing
5’ RLM-RACE was performed using the GeneRacer 
Kit (Invitrogen) with some modification as previously 
described. [35] Briefly, 100 ng total RNA was directly 
ligated to 250 ng GeneRacer RNAOligo with T4 
ligase. After phenol/chloroform extraction and ethanol 
precipitation, cDNA was synthesized using random 
primers. From this reaction, 1 μl was used for first round 
5’RACE reaction using the GeneRacer 5’primer and 
gene-specific primers (GAPD-specific reverse primer, 
5’-CCTGCAAATGAGCCCCAGCCTTCTC-3’or BCL-XL- 
specific reverse primer, 5’-TCTACGCTTTCCACGCA 
CAGTGCCC-3’) with the following cycling conditions: 
1 cycle of 94 °C for 2 minutes, then 5 cycles of 94 °C for 
30 seconds and 72 °C for 1 minute, then 5 cycles of 94 
°C for 30 seconds and 70 °C for 1 minute, then 20 cycles 
of 94 °C for 30 seconds, and 68 °C for 1 minute. Second-
round 5’ RACE reaction was then performed using 1 
μl of the first-round reaction and internal GeneRacer 
5’ nested and gene-specific primers (GAPD-specific 
nested, 5’-CGCCAGCATCGCCCCACTTGATTTT-3’or 
BCL-XL-specific nested, 5’-GCTGTCCCTGGGGTGA 
TGTGGAGCT-3’) using the above cycling conditions 
except for an extension time of 15 seconds and 25 cycles. 
PCR were performed using an Eppendorf Mastercycler 
thermocycler. PCR products were run on a 3% agarose gel 
containing ethidium bromide then excised and extracted 
using a QIAquick Gel Extraction kit (Qiagen). Sequencing 
was performed using the ABI BigDye Terminator v3.1 Cycle 
Sequencing kit and subsequently analyzed on an ABI-3730xl 
DNA Analyzer (Applied Biosystems) per manufacturer′s 
protocol.
Immunoblotting
Protein gel electrophoresis was performed by loading 
5 μg of cell lysate per lane on a 4-12% Bis-Tris NuPAGE 
gel (Invitrogen) followed by transfer to a PVDF membrane 
(Invitrogen). The membrane was blocked with 5% Milk/TBS 
(0.1%Tween20), prior to overnight incubation with primary 
antibody incubation at 4°C. Secondary antibody probing 
(Polyclonal Goat Anti-Rabbit Immunoglobulins/HRP; Dako; 
Carpinteria, CA) was done for 1 hour at room temperature. 
Results were visualized using Amersham ECL Western 
Blotting Detection Reagents (GE Healthcare; Pittsburg, PA) 
and Amersham Hyperfilm ECL (GE Healthcare). Reprobing 
to verify loading control was done after rinsing the membrane 
and reblocking before subsequent antibody probing. BCL-XL 
(clone 54H6), GAPD (clone 14C10), and beta-actin (clone 
13E5) antibodies for immunoblotting were obtained from 
Cell Signaling Technologies (Danvers, MA).
In vitro toxicity analysis
Cells were plated in quadruplicate at a cell density 
of 5,000 cells/well in white 96-well plates on the day prior 
to treatment. Cells were treated with polyplexes for 2 
hours then harvested 48 hours later and assayed using the 
CellTiter-Glo Luminescent Cell Viability Assay (Promega) 
per manufacturer’s instructions. Microplates were read 
on a Centro LB 960 microplate luminometer (Berthold 
Technologies).
GAPD protein assay
GAPD enzyme activity was quantitated using the 
KDAlert GAPDH assay kit (Ambion) per manufacturer’s 
recommendations. Cells were treated in quadruplicate then 
lysed 72 hours later. Lysate was transferred to a 96-well 
plate and KDAlert master mix added. The fluorescence 
intensity was measured over 4 minutes using an excitation 
wavelength of 560 nm and emission wavelength of 590 nm.
Xenograft experiments
5-6 week old female athmyic nu/nu mice weighing 
approximately 20 grams were obtained from Harlan 
Laboratories. Animals were housed in specific pathogen-
free housing. All experiments were performed with the 
approval of the Fred Hutchinson Cancer Research Center 
Institutional Animal Care and Use Committee. 10 million 
SKOV3 luciferase-expressing cells suspended in sterile 
PBS (Gibco) were injected intraperitoneally. For imaging 
studies, mice were injected intraperitoneally with firefly 
D-luciferin (Biosynth International, Inc; Itasca, IL) at 
150 micrograms per gram of body weight and tumor 
establishment was verified by in vivo bioluminescence 
imaging using the Xenogen Spectrum system (Perkin 
Elmer; Waltham, MA). Mice were separated into treatment 
groups with similar average bioluminescence intensity and 
then injected intraperitoneally with Cy5.5-labeled siRNA 
alone, a trastuzumab-targeted polyplex containing Cy5.5-
labeled siRNA, or sterile PBS alone. After 24 hours, mice 
were euthanized via carbon dioxide inhalation. Organs were 
removed and imaged in an ex vivo fashion. Kidney, liver, 
and tumor nodules were flash frozen for further analysis. For 
functional siRNA delivery experiments, mice were injected 
intraperitoneally with 2 or 4 mg/kg siRNA once daily for two 
days then euthanized via carbon dioxide inhalation 72 hours 
after the second dose. Blood for laboratory toxicity analysis 
was harvested via cardiac puncture. Tumor and spleen were 
placed in RNAlater (Qiagen) for RNA extraction for qRT-
PCR and 5’RACE analysis (tumor only).
RNA extraction and quantitation from tissue
RNA was extracted from mouse tissues as previously 
described. [36] Briefly, samples were homogenized in 
guanidine thiocyanate lysis buffer with the FastPrep-24 
instrument (MP Biomedicals; Solon, OH) and Lysing 
Matrix D tubes (MP Biomedicals). Samples were 
immediately centrifuged at 4°C, extracted with phenol-
chloroform and RNA precipitated with isopropanol and 
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sodium acetate (Ambion) overnight at -20°C. Further RNA 
purification was performed using the RNeasy kit (Qiagen; 
Valencia, CA) per manufacturer’s instructions after adding 
350 μl RNEasy RLT buffer and 100 μl 100% ethanol to 
the resuspended RNA pellet. Residual DNA contamination 
was removed with the Turbo DNA-Free kit (Ambion). The 
supernatants were collected and quantitated via UV-Vis for 
concentration analysis.
Biodistribution
Quantification of Cy5.5-labeled siRNA in tissues 
was performed as previously described. [37] Briefly, 
tissue was homogenized in PBS with the FastPrep-24 
instrument and Lysing Matrix D tubes. Homogenates 
were centrifuged to remove insoluble tissue debris. The 
fluorescence intensity of the supernatant was analyzed 
using a Synergy H4 microplate reader (BioTek; Winooski, 
VT) at 675 and 694 nm of excitation and emission 
wavelength, respectively. The moles of siRNA per gram of 
tissue was determined by using a standard curve generated 
by diluting 0.5 μmoles of Cy5.5-labeled GAPD siRNA 
1:2 in PBS in succession six times. Tissue samples were 
diluted 1:2 in PBS before being read in duplicate along 
with the standards and a blank PBS sample.
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